Remarkable progress in cancer research and outcomes

- Increase in R01 Applications to NCI
- Pharmaceutical industry investment in cancer drugs
- Declining cancer mortality, even in lung cancer and melanoma
- Record numbers of cancer drug approvals by FDA in 2018 & 2019

**AMONG U.S. MEN**

DEATHS FROM THE MOST COMMON TYPE OF LUNG CANCER

- **FELL**
  - 3.2% EACH YEAR FROM 2006 TO 2013

- THEN FELL
  - 6.3% EACH YEAR FROM 2013 TO 2016

*AAPC is significantly different from zero (p<.05).*